Ferring Pharms Inc patents expiration
1. Cervidil patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5269321 | FERRING PHARMS INC | Retrievable pessary |
Jul, 2012
(11 years ago) | |
Drugs and Companies using DINOPROSTONE ingredient
Market Authorisation Date: 30 March, 1995
Treatment: Use as a retrievable pessary
Dosage: INSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL family patents
2. Clenpiq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11191753 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(10 years from now) | |
| US10624879 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(10 years from now) | |
| US9827231 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 15, 2021 |
Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy
Dosage: SOLUTION;ORAL
CLENPIQ family patents
3. Ddavp patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5500413 | FERRING PHARMS INC | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
Jun, 2013
(10 years ago) | |
| US5763407 | FERRING PHARMS INC | High-purity desmopressin produced in large single batches |
Jun, 2013
(10 years ago) | |
| US5674850 | FERRING PHARMS INC | High purity desmopressin produced in large single batches |
Dec, 2013
(10 years ago) | |
| US7022340 | FERRING PHARMS INC | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
Apr, 2023
(11 months ago) | |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 06 September, 1995
Treatment: NA
Dosage: TABLET;ORAL; SPRAY, METERED;NASAL; INJECTABLE;INJECTION; SOLUTION;NASAL
DDAVP family patents
4. Ddavp (needs No Refrigeration) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5482931 | FERRING PHARMS INC | Stabilized pharmaceutical peptide compositions |
Jun, 2013
(10 years ago) | |
| US5763407 | FERRING PHARMS INC | High-purity desmopressin produced in large single batches |
Jun, 2013
(10 years ago) | |
| US5500413 | FERRING PHARMS INC | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
Jun, 2013
(10 years ago) | |
| US5674850 | FERRING PHARMS INC | High purity desmopressin produced in large single batches |
Dec, 2013
(10 years ago) | |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Treatment: NA
Dosage: SPRAY, METERED;NASAL
DDAVP (NEEDS NO REFRIGERATION) family patents
5. Milprosa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10548904 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(4 years from now) | |
| US10537584 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(4 years from now) | |
| US8580293 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Jan, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2023 |
Drugs and Companies using PROGESTERONE ingredient
Market Authorisation Date: 29 April, 2020
Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women
Dosage: SYSTEM;VAGINAL
MILPROSA family patents
6. Nocdurna patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9919025 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(11 months ago) | |
| US9220747 | FERRING PHARMS INC | Methods using desmopressin acetate in orodispersible form |
May, 2023
(11 months ago) | |
| US9504647 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(11 months ago) | |
| US10307459 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(11 months ago) | |
| US7947654 | FERRING PHARMS INC | Pharmaceutical formulations |
Dec, 2023
(3 months ago) | |
| US8802624 | FERRING PHARMS INC | Methods of treatment using orodispersible desmopressin pharmaceutical formulations |
Dec, 2023
(3 months ago) | |
| US7560429 | FERRING PHARMS INC | Orodispersible dosage forms of desmopressin acetate |
Feb, 2024
(2 months ago) | |
| US10137167 | FERRING PHARMS INC | Methods comprising desmopressin |
May, 2029
(5 years from now) | |
| US11020448 | FERRING PHARMS INC | Methods comprising desmopressin |
May, 2029
(5 years from now) | |
| US9974826 | FERRING PHARMS INC | Methods comprising desmopressin |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 21, 2021 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 21 June, 2018
Treatment: Treatment of nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration
Dosage: TABLET;SUBLINGUAL
NOCDURNA family patents
7. Prepopik patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8481083 | FERRING PHARMS INC | Granular compositions of magnesium oxide and citric acid and uses thereof |
Oct, 2028
(4 years from now) | |
| US8450338 | FERRING PHARMS INC | Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof |
Oct, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 15, 2021 |
| New Product(NP) | Jul 16, 2015 |
Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient
Market Authorisation Date: 16 July, 2012
Treatment: NA
Dosage: FOR SOLUTION;ORAL
PREPOPIK family patents